Document:

Exhibit 10.3

 

MANUFACTURING FRAMEWORK AGREEMENT

 

This Manufacturing Framework Agreement
(“MFA”) is entered into as of this 20th day of March, 2014 ("Effective Date") between:

 

		(1)	Austrianova Singapore Pte. Ltd., a Singapore corporation having its registered office
and principal place of business at 20 Biopolis Way, #05-518 Centros, Singapore 138668. Reg. No. 200705334K (“Manufacturer”),
and

 

		(2)	Nuvilex, Inc., a Nevada corporation, having its principal office at 12510 Prosperity Drive,
Suite 310, Silver Spring, Maryland 20904, Nevada Reg. No. C22368-1996 (“Client”).

 

Manufacturer and Client are individually
hereinafter referred to as “Party” and collectively hereinafter referred to as “Parties”.

 

BACKGROUND

 

Whereas,
Manufacturer and Client are parties to that certain Asset Purchase Agreement as more particularly defined and described in Definition
"A" below, which provides Client with ownership of certain exclusive licenses that Client will use for the testing of
certain cancer products;

 

Whereas,
in furtherance of the Asset Purchase Agreement the Parties wish to enter into this MFA to set forth the terms and conditions under
which Manufacturer shall manufacture and supply Client with encapsulated 22P1G and/or recloned 22P1G cells (collectively "22P1G
cells"), the latter of which is presently ongoing, to enable Client to have the 22P1G cells necessary for certain clinical
indications involving clinical testing in pre-clinical and clinical phases through Phase 2;

 

Whereas,
this MFA supersedes with respect to clinical production and supply of the 22P1G cells, any prior verbally agreed terms or previous
terms set forth in section 8 and SG Austria’s obligations, points (b) and (c) on pages 9 and 10 of the Asset Purchase Agreement
as applied to the encapsulated 22P1G cells and such resulting product for clinical testing in pre-clinical and clinical
phases through Phase 2;

 

Whereas,
this MFA is designed for Phase 2 trial material utilizing the encapsulated 22P1G cells, and

 

Whereas,
should it become necessary to make material through a Phase 2/3 trial or a straight Phase 3 trial, then within one year of this
Agreement being executed and the first two batches delivered and received by Client, both parties will negotiate in good faith
for a new Manufacturing Agreement to be made for Pivotal Trial Supply and bridging commercial supply and eventual commercial manufacturing.

 

Now,
therefore, in consideration of the foregoing promises and the covenants and obligations set forth in this MFA,
the Parties agree as follows:

 

    	1

    	 

    

 

DEFINITIONS

 

Capitalized terms used,
but not defined in this MFA, will have the same meaning assigned to them in the Asset Purchase Agreement. “Sections”
refer to the sections of this MFA, unless explicitly provided to refer to a section or article of the Asset Purchase Agreement.
As used in this MFA, the following capitalized terms will have the following meanings:

 

 

		A.	“Asset Purchase Agreement” will mean the “Third Addendum to the Asset
Purchase Agreement” dated June 25, 2013 by and between Manufacturer and the Client.

 

		B.	“AI” will mean the “Active Ingredient,” consisting of 22P1G and any of
its derivative cells ("Cells"), which will be supplied by Client as at least ten vials of fully tested and validated
Working Cell Bank cells, each vial containing at least 2 x 106 viable frozen cells. Client shall provide to Manufacturer
all detailed protocols for the maintenance and cultivation of the Cells for manufacturing.

 

		C.	“Confirmation Date” will mean the date on which written confirmation of the
delivery date is given by Manufacturer to Client relating to a Purchase Order.
	 	 	 

		D.	“Goods” will mean the encapsulated 22P1G cells made by encapsulating the AI
as described in the Specifications set forth in Appendix A attached hereto.

 

		E.	“Lot” will mean a single production run of the Goods.

 

		F.	“MFA Effective Date” will mean the date on which this MFA is executed.

 

		G.	“Purchase Order” will mean Client’s written order for the Goods. The requirements
for the contents of the Purchase Order are as provided in Section 1.11.

 

		H.	“GMP” and “cGMP” will mean Good Manufacturing Practice(s)
and current Good Manufacturing Practice(s), respectively.

 

		I.	“Setup” will mean the initial process and work to create the capability(ies)
to create the environment and to establish and design the correct parameters for the manufacturing process and all other aspects
of the GMP facility such that manufacturing of the final cGMP product can be undertaken by Manufacturer.

 

“Clinical
Forecast” shall mean an overview consisting of Study Information (including Study Name, Registration Number, Test Article,
Study Type and Status), Accrual Metrics (including Number of Sites, Number of Subjects and Accrual Rate – both Planned and
Actual), and the Study Milestones Timeline (including Study Start, Enrollment Complete, Data Lock, Reports Planned and Study Completion
– both Planned and Actual).

 

		J.	“Ex-works” shall mean delivery from Manufacturer's facility to shipper or another
party designated by Client.

 

		K.	“MCB” shall refer to the AI produced in the first amplification after cloning
of the 22P1G cells, also known as the Master Cell Bank.

 

		L.	“WCB” shall refer to the cells produced by the amplification of the AI from
the MCB, also known as the Working Cell Bank.

 

		M.	“US FED” shall mean the Federal Reserve (Central Bank) of the United States.

 

		N.	"Capsule" shall mean the product of the manufacturing process using of the “Cell-in-a-Box®”
technology in which eukaryotic cells are encapsulated in a polymer where one constituent of the encapsulation material is cellulose
sulphate and the other polydiallyldimethylammonium chloride.

 

 

    	2

    	 

    

 

OPERATIVE PROVISIONS

 

1. Manufacturing and Supply of
the Goods 

 

		1.1	Manufacturer shall manufacture and supply the Goods to Client on the terms set forth in this MFA
and any applicable Purchase Order.

 

		1.2	Manufacturer may supply Client either directly by Manufacturer itself manufacturing the Goods,
and/or indirectly, by providing Goods from one or more of Manufacturer‘s Affiliates, a Third Party and/or Third Parties.

 

		1.3	The Goods to be manufactured and supplied to Client by Manufacturer under this MFA consist of two
components: (i) the AI and (ii) the Capsule. The components of the Capsule will be supplied by Manufacturer.

 

		1.4	A Setup will be undertaken by Manufacturer to establish and design the correct parameters for the
manufacturing process. Subsequent use of the same AI will not necessitate any additional modification of the original Setup. The
Setup costs (“Setup Fee”) will be borne by Client and are described in this MFA.

 

		1.5	Following completion of the Setup, Manufacturer and Client will agree on the final specifications
for the encapsulation of the AI as described in Appendix A and make any necessary changes to generate Appendix B. Any subsequent
changes to the specifications for the AI will be recorded in a similar way. All changes will be appended to, and become part of,
this MFA in an amended form as a new Appendix to this MFA. Any changes to the specifications may entail an additional Setup Fee(s).

 

		1.6	The Goods will be manufactured according to GMP/cGMP standards and to the Specifications agreed
between Manufacturer and Client. Client will supply the AI, including relevant external documentation from an accredited external
provider to evidence that the AI is free of adventitious agents. Client can arrange this external documentation directly or, in
the event that Client wishes Manufacturer to conduct the external testing to determine that the AI is adventitious agent free,
Manufacturer will arrange all necessary testing and charge Client at the actual cost plus an administration fee of 7.5% of the
cost of the tests listed below in addition to the agreed set-up fee and manufacturing costs/vial. Necessary tests for such adventitious
agent free testing may include, but are not be limited to:

 

Identity:

Isoenzymes

DNA Fingerprinting

Others required
by regulatory authorities and/or regulatory consultants

 

Microbial
Contaminants:

Sterility according to European
Pharmacopeia/United States Pharmacopeia/Japanese Pharmacopeia

Mycoplasma according to European
Pharmacopeia/United States Pharmacopeia/Japanese Pharmacopeia

 

    	3

    	 

    

 

General Adventitious
Viruses:

28-day in vitro assay for the
presence of viral contamination using 3 cell lines (Vero, MRC-5 and, in addition, cells of the same species as the test sample).

In vivo assay for the presence
of adventitious agents in suckling and adult mice, embryonated eggs and/or guinea pigs.

 

Retrovirus
Tests:

Transmission
electron microscopy (“TEM”)

Retrovirus
infectivity test

- Extended
S+L- focus assay for amphotropic and xenotropic retroviruses .

- Reverse transcriptase assay
using the PERT assay (“FPERT”) (required if TEM and infectivity test via co-cultivation is negative)

 

Other Viruses:

Mouse antibody
production test (“MAP”)

Hamster antibody
production test (“HAP”)

Bovine viruses

Porcine viruses

 

Human
viruses:

Standard PCR package: (includes
HBV, HCV, EBV, CMV, HIV 1 & 2, HTLV I & II, HHV 6 to HHV8, SV40 and PB19)

Co-cultivation
test using rhabdomyosarcoma (RD) cells for endogenous viruses

 

			The exact choice of tests to be completed in the external testing shall be mutually discussed and
agreed to between Client and Manufacturer dependent on the origin, history, results of previous testing (if any) and materials
with which the AI has come into contact. For clarity, Client will be entitled to specify the exact nature of the tests required
after such discussion in the event of a disagreement between the Parties. Client shall be responsible for the cost of tests it
requires as set forth above in addition to the agreed set-up fee and manufacturing costs/vial, unless Manufacturer performs any
tests not requested by Client in which case the cost of all such tests shall be borne by Manufacturer.

 

		1.7	Manufacturer will admit the AI into the cGMP manufacturing facility upon Manufacturer’s sole
and complete satisfaction with all previous documentation of any and all prior handling of the AI (including materials and substances
that the AI has been in contact with in its complete history) and the evidence showing the AI to be adventitious agent free.

 

		1.8	Client will specify, and Manufacturer will have tested during the Setup, any non-standard substances
required for the culture and expansion of the AI. Such substances will be detailed in the specific AI specifications and shall
be purchased directly by Manufacturer at cGMP grade, with proper documentation and after audit by Manufacturer. The costs of the
audit and the purchase of the non-standard substances will be borne by Client in addition to the agreed Setup Fee and manufacturing
costs/vial. Non-standard growth substances are any media or component(s) required for the attachment, growth, release or activity
of the AI apart from standard cell culture media specifically Dulbecco’s Modified Eagles Medium (DMEM), Roswell Park Memorial
Institute Medium (RPMI), trypsin substitutes, phosphate buffered saline, Dimethyl Sulfoxide (DMSO), high-grade cGMP quality water,
fetal bovine serum, calf serum and horse serum, all of which must be porcine-component free and must be of US origin. Examples
of such non-standard substances would be growth factors, adhesion matrices, such as collagen or laminin, and cell culture media
apart from DMEM or RPMI.

 

    	4

    	 

    

 

 

		1.9	Client will specify and Manufacturer will have tested during the Setup, any non-standard assays
required as In Process Controls (“IPC”) or as release assays. Such assays will have to be set up and validated
by Manufacturer prior to acceptance of the first manufacturing Purchase Order. Such assays or IPCs will be detailed in the specific
AI specifications. The cost of set-up, reagents, equipment and assay validation for such non-standard assays will be borne by Client
in addition to the agreed Setup-Fee and manufacturing costs/vial. For the avoidance of doubt, non-standard assays are assays in
addition to the following standard assays for use in assessing various aspects of the cell production and encapsulation:

 

	 	Standard Items to Assess During and/or After Production
	 	 
	 	Cell Morphology	Turbity
	 	Cell Homogenicity	Osmolarity
	 	Cell Vitality before Encapsulation	Cell Number and Concentration Measurements
	 	Glucose Concentration	Sterility
	 	pH	Endotoxin
	 	Bioburden in Supernatant	Cells per capsule
	 	Mycoplasma	Capsules per Vial
	 	Cell Viability	Cell Viability in Capsules

 

		1.10	The first Clinical Forecast is attached to this MFA as "Exhibit A." Each Calendar Quarter
(every three months) after the Effective Date and for the duration of the term of this MFA, Client and Manufacturer will mutually
agree upon a new Clinical Forecast by the thirtieth (30th) day into such Calendar Quarter, rolling forward one (1) Calendar Quarter
in each forecast. Such Clinical Forecast will cover the immediately succeeding twelve (12) months after the Calendar Quarter in
which it is agreed. Each Clinical Forecast will state the requested delivery date for each shipment. The amounts and dates set
forth for the first Calendar Quarter in each Clinical Forecast will constitute a firm Purchase Order and will be binding upon Client.
The Purchase Order portion of the Clinical Forecast must comply with Section 1.11 of this MFA to the extent applicable. The
remainder of such Clinical Forecast will be for information purposes only. Manufacturer will reasonably cooperate with Client to
seek to accommodate Client’s timing requests for clinical supply. However, Manufacturer will not be required to supply on
less than six (6) months notice for the first 3 purchase orders and thereafter at three (3) month’s notice provided that
this is considered feasible at the discretion of Manufacturer based on the current experience gained in the first 3 purchase orders
and Manufacturer’s supply is subject to the scheduling and availability of its suppliers and subcontractors for the Goods.
Manufacturer’s supply obligations are contingent on Client’s timely and full payment of invoices in accordance with
Section 2 of this MFA. As an example and not by way of limiting the foregoing, in the event the Parties timely agree on a Clinical
Forecast, the Clinical Forecast shall constitute a Purchase Order and a Confirmation Date Notice. Manufacturer will then use its
commercially reasonable efforts to comply with the manufacturing timeline set forth in the Purchase Order and will notify Client
of the timeframe in which the Goods will be manufactured and shipped in accordance with Section 1.13 of this MFA. If such timeframe
is accepted by Client and if Client has paid all costs previously owed and not in dispute, production shall be initiated in accordance
with the terms of the Purchase Order. In the event of delays by Manufacturer’s suppliers and/or subcontractors, adjustments
to the Clinical Forecast will be made accordingly.

 

		1.11	Client will either include all relevant terms in each Clinical Forecast to become a Purchase Order
as described in Section 1.10 of this MFA or will deliver a Purchase Order to Manufacturer at the same time as its proposal for
each update to the Clinical Forecast, as applicable. Purchase Orders will specify the Goods ordered, the quantity ordered and the
requested delivery date(s) for each quantity. The Purchase Order will also specify the carrier who will collect the Goods from
the manufacturing facility of Manufacturer.

 

    	5

    	 

    

 

 

		1.12	If the terms and conditions of any Clinical Forecast, Purchase Order or any other document furnished
by Client to Manufacturer under this MFA conflict with the terms and conditions of this MFA, the terms and conditions of the Purchase
Order or Clinical Forecast will prevail.

 

		1.13	Manufacturer will, within twenty (20) days of the receipt of any Purchase Order from Client, give
written notice to Client of the dates by when manufacturing will be complete and the Goods subject to that Purchase Order will
be shipped (“Delivery Date”).

 

		1.14	Manufacturer will supply quantities of Goods in batches based on the controlling Purchase Order
made between Client and Manufacturer, but with a minimum batch size for any production run of four hundred (400) vials with each
vial containing three hundred (300) Capsules. If for any reason, including, but not limited to, regulatory matters, cell functionality,
cell number per Capsule or similar matters, Client requests a change in the quantity of Goods requested or the minimum size of
any batch, Client and Manufacturer shall work to determine the feasibility of providing the requested quantity of Goods and whether
there will be any adjustment in price as a result. In addition, Manufacturer will notify Client of the then-standard manufacturing
and production batch size for Goods from time to time, although any change must be provided to Client at least 180 days prior to
such change taking place in order for Client to be able to notify regulatory authorities and any other necessary individuals or
groups.

 

		1.15	Shipping will be by ex-works delivery to the carrier. Subject to Force Majeure, Manufacturer
will deliver the Goods to the carrier within ten (10) Business Days of the Delivery Date specified in Manufacturer’s confirmation
of delivery dates under Section 1.13 of this MFA for such shipment. Client will be responsible for the full cost of any freight,
postage, shipping, insurance charges and any other costs associated with shipment of the Goods. Manufacturer will work with Client
to ensure clearance of each shipment of Goods through customs in the country of manufacture and in the country of destination,
but it is Client’s responsibility to obtain all necessary approvals or permits required for the Goods to leave the country
of origin in accordance with Section 1.19 of this MFA. If the carrier refuses to accept Manufacturer’s shipment for any reason
related to Client’s obligations to the carrier, Manufacturer shall not be in breach of the terms and conditions of this MFA
as a result of such refusal, but will be obligated to receive the shipment back and to properly store such shipment to ensure its
efficacy as long as feasible until such proper clearance can be accomplished if the Goods have not left the country of manufacture
at Client’s sole expense. Should Manufacturer have to store the shipment for such a period that the Goods expire, Client
will be responsible of all and any loss.

 

		1.16	Manufacturer will number each shipment with a vendor Lot number that allows the Parties to trace
raw materials and/or components used to manufacture such shipment.

 

		1.17	At least ten (10) days prior to shipment of Goods, Manufacturer will deliver to Client, on a Lot
by Lot basis, a “Certificate of Analysis,” which shall include a complete analysis of the Goods after their
manufactory, including a lot number, specifications for the Capsules, the number of Cells and any other appropriate assessment
of the Goods. The Certificate of Analysis shall also include a list of all adventitious agents that are not normal constituents
of the Cells or Capsules, which shall include, but not be limited to, all bacteria, fungi, mold, mycoplasma, viruses, prions or
similar agents.

 

		1.18	Client is responsible for obtaining any necessary import permits to allow the importation of the
Goods into the United States or its territories, or any other country of destination, for storage or clinical testing. Manufacturer
shall cooperate with Client to ensure such clearance of each shipment of Goods in the country of destination, at Client’s
sole expense.

 

    	6

    	 

    

 

 

		1.19	Client shall be responsible for the successful clearance of the Goods from the country of manufacture.

 

		1.19.1	Manufacturer shall use commercially reasonable efforts to obtain GMP compliant release of the Goods
according to Thai or other regulatory bodies of the country of manufacture. Manufacturer shall implement the necessary steps and
systems to allow any required audits and certification to take place.

 

		1.19.2	Any costs incurred for ensuring GMP compliant release of Goods from the country of manufacture
will be shared equally between Manufacturer and Client.
	 	 	 

		1.19.3	Manufacturer shall not ship any Goods until it has received a signed written approval from Client.
When Manufacturer releases the Goods, it shall provide Client with a Certificate of Analysis along with full documentation

 

		1.20	The Goods to be manufactured and supplied to Client by Manufacturer under this MFA shall be delivered
as frozen product on an ex-works basis. Client assumes all responsibility for and will bear all freight costs, tax and import duties
and any import formalities or administrative tasks.

 

		1.21	Once each shipment of Goods has been accepted by the carrier, Client shall be responsible for all
further distribution and storage of the Goods in that shipment. Client shall store and distribute such quantities of the Goods
in accordance with applicable industry norms and standards and with due regard to the specifications, to the extent applicable,
and any and all relevant regulatory requirements.

 

		1.22	Manufacturer and Client agree that the Goods are to be used only as a component part of a series
of planned preclinical studies and clinical trials through Phase 2 trials and for no other purpose whatsoever.

 

		1.23	Either Party may at any time request that the Goods be adapted/amended in order to comply with
any applicable safety or other statutory requirements. If the changes induced by such adaptation/amendment materially affect the
cost, nature or quality of the Goods, the Parties shall renegotiate in good faith the relevant provisions of this MFA. However
any such adaptation/amendment may necessitate, through discussion between Manufacturer and Client, a new Setup study, the costs
of which, as regulated in Section 2.1 of this MFA, will be the responsibility of Client. Any and all changes to the Specifications
will be recorded in a new Appendix to this MFA as described in Section 1.5 of this MFA.

 

2. Payment

 

		2.1	The costs for the Setup for the AI will be borne by Client and will be six hundred and forty seven
thousand US dollars (USD 647,000) adjusted according to the year (see Section 2.4 of this MFA), of which 50% will be paid upon
the Effective Date and the balance consisting of the remaining 50% will be paid within three months of the Effective Date.

 

		2.2	Client will pay Manufacturer six hundred and forty seven US dollars (US$ 647) adjusted according
to the year (see Section 2.4 of this MFA) per vial of encapsulated 22P1G cells shipped ex-factory.

 

    	7

    	 

    

 

		2.3	Upon confirmation of the delivery date by Manufacturer pursuant to Section 1.13 of this MFA, Manufacturer
will be entitled to submit invoices therefor to Client. Payment for the Goods will be in three parts: (i) one third of the total
cost of the Purchase Order will be payable within thirty (30) days of receipt of the confirmed delivery date; (ii) one third will
be payable within ninety (90) days of receipt of the confirmed delivery date; and (iii) the final one third will be payable within
thirty (30) days of receipt of the Goods by the carrier ex-works.

 

		2.4	Prices quoted for the Setup and the cost per vial are valid for 2014 and thereafter will be increased
yearly according to the annual inflation rate in the country in which the Goods are manufactured according to the GDP Inflation
Rate figures (http://www.gdpinflation.com). At the time of this MFA, the country of manufacture shall be Thailand.

 

		2.5	At Effective Date and as publicized in website www.x-rates.com, 1
USD = 32.51Thai Baht (“Exchange Rate). Should the Exchange Rate differ by more than
five percent (5%), Client and Manufacturer agree that prices mentioned in 2.1 and 2.2 above will be adjusted accordingly. At January
31, 2014, the Thai Consumer Index Price was 106.46 according to website www.gdpinflation.com. Should the CPI at moment of ordering
the Goods, differ by more than 5 points compared to that as at January 31, 2014 of 106.46, Client and Manufacturer agree that the
price mentioned 2.1 and 2.2 will be adjusted accordingly.

 

		2.6	Any additional costs for adventitious agent testing, for non-standard substances, IPCs or release
assays will be detailed in the specifications for the AI and billed to Client in addition to the agreed set-up fee and manufacturing
costs/vial based on the determination of what constitutes standard and non-standard substances as noted in Section 1.8 of this
MFA. A seven and one-half percent (7.5%) administration charge will be charged for third-party services contracted by Manufacturer
on behalf of Client, such as testing or assay services.

 

	2.7	Upon submission of each Client Purchase Order to Manufacturer, Client will disclose full details of the nature of the AI required
to be manufactured. Further, Client will deliver at least ten (10) tubes of AI, each frozen tube containing at least 2 x 106
cells to be encapsulated that are from a fully tested and validated WCB, having already been produced from an MCB, and will
provide the full testing and validation documentation for both the MCB and WCB from their respective manufacturers.

 

3. Late Payment and Interest

 

If payment is not made on the
due date, Manufacturer shall be entitled, without limiting any other rights it may have, to charge Client interest on the outstanding
amount (both before and after any judgment). Interest shall accrue on sums outstanding after the due date for payment at the rate
of five percent (5%) per annum over the US FED base rate. Further, if payment is not made more than thirty (30) days after the
due date, Manufacturer will have the right to suspend or cease production with an obligation to resume only upon further payment.
Any payments already made by Client to Manufacturer will be deemed non-refundable if, once Client has made a decision to terminate
a project, the project is not reopened within sixty (60) days of the written notice to Manufacturer of such termination.

 

4. Quality of the Goods 

 

		4.1	In entering into this MFA, Client relies on Manufacturer’s expertise to manufacture the Goods,
and Manufacturer accordingly warrants to Client that all Goods under this MFA shall:

 

		4.1.1	Conform in all respects to the specifications agreed between the Parties as a result of the data
gained in the Setup;

 

    	8

    	 

    

 

 

		4.1.2	For a period of twenty-six (26) weeks following delivery of the Goods, so long as the Goods
have been verifiably transported and stored according to Manufacturer’s instructions, the Goods shall be warranted to meet
the quality required by the specifications and to be free from defects in design, workmanship or materials. In case of delivery
of defective or non-conforming Goods, Manufacturer shall remedy the defect or the non-conformity within thirty (30) days after
receipt of a written notice from Client giving full particulars of the defect or the non-conformity, together with a transcript
of the transport and storage conditions (e.g. by shipper’s and Client data logger); and

 

		4.1.3	If the defect or the non-conformity amounts to a material breach of any of the provisions of this
MFA or a Purchase Order and Manufacturer fails to remedy the breach within ninety (90) days after receipt of written notice of
the defective Goods, Client shall be entitled to receive a credit or terminate this MFA pursuant to Section 7.2.1 of this MFA,
all at Client's sole discretion.

 

		4.2	If any claim is made against Manufacturer by a third party arising out of or in connection with
the manufacture of the Goods, Client shall indemnify Manufacturer against all damages or other compensation awarded against Manufacturer
in connection with the claim or paid or agreed to be paid by Manufacturer in settlement of the claim which is approved by Client,
which approval shall not be unreasonably withheld or delayed, and all reasonable legal or other expenses incurred by Manufacturer
in or about the defense or settlement of the claim. Manufacturer shall notify Client as soon as practicable after becoming aware
of the claim and take all action reasonably requested by Client to avoid, compromise or defend the claim and any proceedings in
respect of the claim, subject to the Manufacturer being indemnified and secured to its reasonable satisfaction against all costs
and expenses which may be incurred in doing so. Notwithstanding the foregoing, the indemnity obligations set forth in Section 4.2
of this MFA shall not apply to any claims based upon any manufacturing defect or defect in the specification or components made
by Manufacturer so long as the claim refers to goods delivered less than 26 weeks previously by the manufacturer or are the result
of the negligence, gross negligence or willful misconduct of Manufacturer.

 

		4.4	Manufacturer and Client shall both obtain comprehensive liability insurance to protect all Parties
prior to starting production of the Goods ordered by Client and will provide each other copies of their insurance policies following
a written request by a Party to do so.

 

5. Intellectual Property

 

		5.1	Intellectual Property (“IP”) shall mean patentable inventions, marks
(including trademarks, service marks, certification marks, and/or collective marks), whether registered or common law, materials
in which copyrights exists and trade secrets. Client or its affiliates are the licensee owning an exclusive license to use the
Cells in the field of oncology treatments in certain territories. For the period of this MFA and for the purposes of exercising
its rights and performing its obligations under this MFA, Client grants Manufacturer a non-exclusive license to manufacture the
Goods using the technology, subject to Client’s or it’s Affiliate’s exclusive license.

 

		5.1.1	Client is granted the non-exclusive right, to apply Manufacturer’s “Cell-in-a-Box”
trademark to the Goods during the term of this MFA.

 

		5.2	All artwork supplied by Client from time to time for use in relation to the Goods or their labeling
and packaging, and all of Client's or Client’s Affiliate’s Intellectual Property shall belong exclusively to Client,
and Manufacturer shall acquire no rights therein.

 

    	9

    	 

    

 

 

		5.3	Client shall, at the request and expense of Manufacturer, take all such steps as Manufacturer may
reasonably require to assist Manufacturer in maintaining Manufacturer’s trademarks. Client shall not represent that it has
any title in or right of ownership to any of the trademarks other than the non-exclusive rights to use the Cell in a Box trademark
granted by separate agreement or do or suffer to be done any act or thing which may in any way impair the rights of Manufacturer
in any of the trademarks or bring into question the validity of its registration.

 

		5.4	Client shall promptly notify Manufacturer of any actual or threatened infringement of any of the
trademarks of which Client becomes aware or which Client suspects has occurred or may occur.

 

		5.5.	New IP generated during the term of this MFA shall be solely owned by Manufacturer if pertaining
to Encapsulation and if generated solely by Manufacturer and shall be solely owned by Client if pertaining solely to the AI and
if generated solely by Client. All other new IP involving arising during the term of this MFA as a direct result of work or intellectual
input by both Client and Manufacturer (“Joint IP”) shall be jointly-owned by Client and Manufacturer. The Parties
will license their respective half of the Joint IP to each other for consideration of $1.00 US.

 

	 	5.5.1	Disclosure of Inventions. A Party must promptly inform the other Party of all IP that it or its officers, employees,
agents or consultants create as part of this MFA and that falls within the scope of this MFA.

 

	 	5.5.2	Creation/Ownership. Creation/Ownership of new IP will be determined in accordance with Singapore patent law.

 

	 	 	5.5.3Filing, Prosecution and Maintenance Joint IP. Filing, prosecution and maintenance of Joint IP will be undertaken
by Client as follows: (i) give Manufacturer a copy of any draft application before it is filed so that Manufacturer can give Client
comments on the substance of the application; (ii) consult with Manufacturer regarding the countries in which patent applications
should be filed; (iii) take all reasonable steps to prosecute all patent applications; (iv) respond to proceedings filed by third
parties against the patent applications; (v) file all papers and, subject to Section 8.2 of this MFA, pay all fees necessary to
maintain any granted patents; (vi) take all actions reasonably requested by Manufacturer to maintain any granted patents; (vii)
give Manufacturer copies of all documents relating to the filing, prosecution and maintenance of patent applications and granted
patents; (vii) upon written request by Manufacturer, give Manufacturer a report detailing the status of all patent applications
and granted patents on or before December 31 of each year this MFA is in effect; and (viii) give Manufacturer prompt notice of
any decision by Client to decline, defer, not file a patent application or to abandon a patent application(s) or a granted patent(s).
After receiving this notice, Manufacturer may, at its sole cost and expense, take over the filing, prosecution or maintenance
of the patent application(s) or granted patent(s). If this occurs, the relevant IP rights will be in assigned to Manufacturer.

 

	 	5.5.4	Abandonment. If Client does not wish to continue to support the filing, prosecution or maintenance of any Joint
IP, it shall immediately notify Manufacturer of such decision in writing. At that point, Manufacturer will have the right to keep
or allow to lapse any and all rights to the Joint IP. All rights as described in the Asset Purchase Agreement supersede any described
herein and shall survive the term or termination of this MFA.

 

    	10

    	 

    

 

 

		5.6	Infringement. Each Party shall promptly notify the other of any third-party claim of infringement
related to any IP. In the event any such claims are made, the Party owning the allegedly infringing IP shall be responsible for
the defense of such claims and shall indemnify and hold harmless the other Party with respect to such claims. In the event an infringement
claim is related to Joint IP, the Parties shall share equally in the defense of any such claim and in any damages related to such
claim.

 

6. Cooperation of the Parties for Improvements
and Modifications

 

		6.1	Client and Manufacturer shall meet either physically or by way of a teleconference at least once
per calendar quarter during the term of this MFA to review any matters likely to be relevant to the manufacture, sale, use or development
of the Goods.

 

		6.2	Without limiting the general scope of Section 6.1:

 

	 	6.2.1  	Client shall provide Manufacturer with details of any improvement belonging to Client that it wishes to be incorporated into the
Goods or any other modification that it wishes to be made to the Goods from time to time; and

 

	 	6.2.2	Manufacturer shall provide Client with details of any improvement
    that is made, developed or acquired by Manufacturer from time to time.

 

		6.3	The term "improvement" as used in this MFA means any development, enhancement
or derivative of the Goods, or its design or manufacturing process, which would make the Goods less expensive to manufacture, more
effective, more useful, more valuable or would in any other way render the Goods preferable in commerce.

 

		6.4	Title to any Intellectual Property rights with respect to any improvement made, developed or acquired
by either Party shall belong to that Party, but Client may use any improvement which is made, developed or acquired by Manufacturer
and any applicable Intellectual Property of Manufacturer relating to the subject matter of this MFA for its own purposes by way
of a non-exclusive, royalty-free license during the term of this MFA and any extensions or renewals hereof.

 

		6.5	Manufacturer shall not unreasonably withhold its consent to the incorporation into the Goods of
any improvement belonging to Client or any other modification to the Goods referred to in Section 6.2.1 of this MFA, or of any
improvement belonging to Manufacturer referred to in Sections 6.2.2 and 6.4 of this MFA. However, any such modification may necessitate,
at the discretion of Manufacturer, a new Setup study, the costs of which, as regulated in Section 2.1 of this MFA, will be borne
by Client.

 

7. Duration and Termination of the MFA

 

		7.1	This MFA shall be effective as of the Effective Date. Unless sooner terminated pursuant to Sections
7.2 or 7.3, this MFA shall continue until terminated by either Party in accordance with the provisions of this MFA .

 

		7.2	Either Party shall be entitled forthwith to terminate this MFA by giving written notice to the
other if:

 

    	11

    	 

    

 

 

		7.2.1	A Party commits any continuing and material breach of any of the provisions of this MFA and fails
to remedy (or to commence and reasonably pursue a cure if the breach is not curable within sixty (60) days) the breach within sixty
(60) days after receipt of a written notice giving the specific details of the breach and requiring it to be remedied.

 

		7.2.2	A creditor takes possession or a receiver is appointed over any of the property or assets of the
other Party;

 

	 	7.2.3 	A Party makes any voluntary arrangement with its creditors or becomes subject to an administration
order related thereto;

 

		7.2.4	The other party goes into liquidation (except for the purposes of an amalgamation, reconstruction
or other reorganization and in such manner that the company resulting from the reorganization effectively agrees to be bound by
or to assume the obligations imposed on that other party under this MFA); or

 

		7.2.5	A Party ceases or threatens to cease to carry on its business.

 

		7.3	Any waiver by either Party of a breach of any provision of this MFA shall not be considered as
a waiver of any subsequent breach of the same or any other provision.

 

		7.4	The rights to terminate this MFA shall not constitute a Party’s ability to exercise any other
right or seek any other remedy contained in this MFA or available by law.

 

8. Consequences of Termination

 

		8.1	Upon the termination of this MFA for any reason, except for reason of non-payment by Client, Manufacturer
shall be required to continue the manufacture of any Goods ordered pursuant to a Purchase Order then in effect, which manufacturing
period shall continue until all Goods have been manufactured or three months, whichever is shorter (“Phase-Out Period”).
During the Phase-Out Period, Client shall be permitted to sell all Goods that have been provided to Client pursuant to this MFA.
At the end of the Phase-Out Period, Client shall offer to sell to Manufacturer all Goods which have been manufactured pursuant
to this MFA, but not sold, and all usable but unused stocks of labeling and packaging for the Goods, at a price equal to their
cost to Client (excluding any fees paid by the Client to Manufacturer above actual cost of the Goods), together with any necessary
royalty-free licenses allowing Manufacturer to resell these Goods and to benefit exclusively from the financial proceeds of these
sales.

 

		8.2	Subject to Section 8.1, on the termination of this MFA for any reason Client shall:

 

		8.2.1	Subject to Section 1.4 of this MFA, cease to sell the Goods or to use, either directly or indirectly,
any of the technology referred to in Section 1.4 or Intellectual Property referred to in Section 5 of this MFA that is owned by
Manufacturer and forthwith return to Manufacturer any documents in its possession or control which contain or record any part of
any of that Intellectual Property.

 

		8.3	Except as provided in Section 8 of this MFA and any accrued rights or obligations pursuant to this
MFA, neither Party shall have any further obligation, contractual or otherwise, to the other.

 

		8.4	The provisions of Section 9 of this MFA shall survive termination of the MFA, regardless of the
reason for termination.

 

 

    	12

    	 

    

 

9. Confidentiality

 

		9.1	Both Parties understand and acknowledge that, by virtue of this MFA, they may both receive or become
aware of technology and information belonging or relating to the other Party, its business, business plans, affairs or activities
which information is confidential and proprietary to the other Party and/or its manufacturers and/or customers and in respect of
which they are bound by a strict duty of confidence (“Confidential Information”).

 

		9.2	As a consequence thereof, neither Party shall, either during the period of this MFA or at any subsequent
time, disclose to any other person Confidential Information disclosed to it by the other Party under this MFA and shall use its
best efforts to keep such Confidential Information (whether marked as such or not), except as provided by Section 9.3 or 9.4 of
this MFA.

 

		9.3	Any of the Confidential Information referred to in Section 9.1 of this MFA may be disclosed to:

 

	 	9.3.1	Any contractor of or supplier to the Party in question of any equipment or products;

 

	 	9.3.2  	Any governmental or other authority or regulatory body; or

 

	 	9.3.3	Any directors or employees or consultants and professional or legal advisers of the Party in question;

 

to such extent only as is necessary for the purposes of this MFA or as required by law, and subject in each case (other than under Section 9.3.2 of this MFA) to the Party in question first obtaining (and submitting to the other Party a copy of) a written undertaking from the person to whom the disclosure is made, as nearly as practicable in the terms of Section 9 of this MFA, to keep it confidential and to use it only for the purposes for which the disclosure is made.

 

		9.4	Any of the Confidential Information referred to in Section 9.1 of this MFA may be used by the Party
in question for any purpose, or disclosed by that Party to any other person, but only to the extent that any part of it is at the
date of this MFA or subsequently becomes public knowledge through no fault of the Party in question; provided, however, that in
so doing such Party does not disclose any part of Confidential Information which is not public knowledge.

 

		9.5	This undertaking and the obligations contained in Section 9 of this MFA shall continue for a period
of 10 years and shall survive termination of this MFA.

 

10. Force Majeure – excuse for
non-performance

 

		10.1	“Force Majeure” means war, emergency, accident, fire, earthquake, flood,
storm, industrial strike or other impediment which the affected Party proves was beyond its control and that it could not reasonably
be expected to have taken the impediment into account at the time of the execution of this MFA or to have avoided or overcome it
or its consequences.

 

		10.2	A Party affected by Force Majeure shall not be deemed to be in breach of this MFA, or otherwise
be liable to the other Party, by reason of any delay in performance or the non-performance of any of its obligations under this
MFA to the extent that the delay or non-performance is due to any Force Majeure of which it has notified the other Party
in accordance with Section 10.3 of this MFA. The time for performance of that obligation shall be extended accordingly, subject
to Section 10.4 of this MFA.

 

    	13

    	 

    

 

 

		10.3	If any Force Majeure occurs in relation to either Party which affects or is likely to affect
the performance of any of its obligations under this MFA, it shall notify the other Party within a reasonable time as to the nature
and extent of the circumstances in question and their effect on its ability to perform.

 

		10.4	If the performance by either Party of any of its obligations under this MFA is prevented or delayed
by Force Majeure for a continuous period in excess of three (3) months, the other Party shall be entitled to terminate this
MFA by giving written notice to the Party affected by the Force Majeure. However all reasonable costs committed by Manufacturer
arising from a Purchase Order received will be reimbursed by Client.

 

 

11. Change of circumstances; Hardship

 

		11.1	Where the performance of this MFA becomes more onerous than reasonably anticipated at the time
of execution of this MFA for one of the Parties, that Party is nevertheless bound to perform its obligations subject to the following
provisions.

 

		11.2	If, during the term of this MFA, events occur that have not been contemplated by the Parties and
which render the MFA fundamentally unfair to that a Party, thereby placing an excessive burden on one of the Parties in the performance
of its contractual obligations (“Hardship”), that Party shall be entitled to request revision of this MFA provided
that:

 

	 	11.2.1	The events could not reasonably have been taken into account by the affected Party at the time of execution of this MFA;

 

	 	11.2.2	The events are beyond the control of the affected Party; and

 

	 	11.2.3	The risk of the events is not one which, according to this MFA, the Party affected should be required to bear (an increase in
the cost of performance for a Party shall not constitute a hardship hereunder).

 

		11.3	Each Party shall in good faith consider any proposed revision seriously put forward by the other
Party in the interests of the relationship between the Parties.

 

12. No Partnership or Agency

 

Nothing in this MFA shall: (i)
be deemed to constitute a partnership in law between the Parties; (ii) make either Party the agent of the other for any purpose;
or (iii) entitle either Party to commit or bind the other Party in any manner.  

 

13. Assignment and Subcontracting

 

		13.1	Subject to Section 1.2, this MFA is
personal to the Parties, and neither Party shall, without the prior written approval of the other:

 

		13.1.1	Assign, mortgage, charge or
otherwise transfer or deal in, or create any trust over, any of its rights; or

 

    	14

    	 

    

 

 

		13.1.2	Subcontract, except by Manufacturer to its sub-contractors or otherwise delegate the whole or any
part of its rights or obligations under this MFA to another person; provided, however: a Party may, without the permission of the
other Party, assign this MFA to: (i) its Affiliates; (ii) any purchaser of all or substantially all of its assets; or (iii) any
successor corporation resulting from any merger or consolidation of such Party with or into such corporations.

 

14. Notices

 

		14.1	Any notice under this MFA shall be in writing (which may include e-mail) and may be served by leaving
it or sending it to the address of the other party as specified in Section 14.2 of this MFA, in a manner that ensures receipt of
the notice can be proved.

 

		14.2	For purposes of Section 14.1 of this MFA, notification details are the registered addresses as
set forth at the beginning of this MFA, unless other details have been duly notified in accordance with Section 14 of this MFA.

 

15. Entire Agreement

 

		15.1	This MFA and the Asset Purchase Agreement constitute the entire agreement between the Parties with
regard to the subject matter hereof. Neither Party has entered into this MFA in reliance upon any representation, warranty or undertaking
of the other Party that is not expressly set out or referred to in this MFA or the Asset Purchase Agreement. This shall not preclude
any liability for fraudulent misrepresentation. In the event of a conflict between the Asset Purchase Agreement and this MFA, the
terms of this MFA shall control and shall supersede any previous agreement or understanding relating to its subject matter; however,
it is the intent of the parties that the Asset Purchase Agreement and the MFA be read and interpreted together, giving meaning
to all terms and conditions wherever and whenever possible.

 

		15.2	This MFA may not be varied except by a signed written agreement between the Parties. If any provision
of this MFA is held by any court or other competent authority to be invalid or unenforceable in whole or in part, this MFA shall
continue to be valid as to its other provisions and the remainder of the affected provision, unless it can be concluded from the
circumstances that, in the absence of the provision found to be null and void, the Parties would not have executed this MFA. The
Parties shall use all reasonable efforts to replace all provisions found to be null and void by provisions that are valid under
the applicable law and come closest to their original intention.

 

16. Dispute resolution

 

Any dispute arising under this
MFA which cannot be resolved by consultation, negotiation and mediation between the Parties shall within ninety (90) days of commencement
of discussions related to the dispute, shall be referred to and finally resolved by arbitration in London, England in accordance
with the Arbitration Rules of the London International Arbitration Centre for which rules are deemed to be incorporated by reference
into Section 16 of this MFA. The language of the arbitration shall be English. Any such arbitration award shall be final and binding
upon the Parties and judgment on such award may be entered into any court or tribunal having jurisdiction thereof.

 

 

    	15

    	 

    

 

17. Applicable Law

 

The validity and interpretation
of this MFA and the legal relations of the Parties to it shall be governed by the laws of Singapore. The United Nations Convention
on Contracts for the International Sale of Goods (Vienna Sales Convention of 1980−CISG) is specifically not applicable to
this MFA. 

 

18. Miscellaneous

 

		18.1	Binding Effect. This MFA is binding upon and inures to the benefit of a Party’s legal
representatives, successors and permitted assigns.

 

		18.2	Counterparts. This MFA may be executed in two or more counterparts, each of which will be
deemed an original and all of which shall constitute together the same document.

 

		18.3	Amendment. This MFA may be amended only by a written agreement between the Parties.

 

		18.4	Waiver. A Party’s compliance with the terms of this MFA may only be waived by written
notice from the other Party. Unless stated otherwise, a waiver will not be deemed an ongoing waiver. The delay or failure of a
Party to require performance of a term of this MFA will not prevent the Party from enforcing the same term later.

 

		18.5	Third Party Beneficiaries. It is the intention of the Parties that no third party will have,
and no third party has, any rights under this MFA.

 

	SIGNED by	)
	 	)
	 	)
	for and on behalf of the	) Dr. Brian Salmons
	        Manufacturer	) CEO, Austrianova Singapore Pte. Ltd.
	 	)
	 	)
	 	)
	 	)
	in the presence of:-	)
	 	)
	 	 
	 	 
	 	 
	SIGNED by	)
	 	)
	 	)
	for and on behalf of the Client	) Kenneth L. Waggoner
	 	) Chief Executive Officer and President of Nuvilex, Inc.
	 	)
	 	)
	 	)
	 	)
	in the presence of:-	)
	 	)

 

 

 

 

    	16

    	 

    

 

 

Appendix A: Specifications for Encapsulated
22P1G Cells

 

	Parameter	Method	Specification Limits
	Visual appearance	EP	Clear,
    coloured £ BG4
	Number of Capsules per vial	Manual Scanner	300 ±
    20 %
	Viability	AlamarBlue Assay	3
    20000 cell equivalents (corresponds to metabolism activity of 20000 not encapsulated HEK 22PIG cells)
	Enzymatic activity	Resorufin Assay	Activity detectable
	Sterility	Membrane Filtration (EP 2.6.1)	sterile
	Purity testing - mycoplasma	Fluorescence method	not detected
	Purity testing - mycoplasma	Co-Culture, PCR	not detected
	Endotoxins	LAL test	£
    10 EY / mL
	pH of supernatant	EP	7.5 ±
    0.5
	Freezing rate	MFGVII-PA-12-103	-0.3
    to -1.00 C/min
	Osmolality of supernatant	QC-PA-10-049/03	Report only
	DMSO assay of supernatant	QC-PA-10-049/Annex01/01	9-11 %

 

 

 

    	17

    	 

    

 

 

Exhibit A: Clinical Forecast

 

Study InformationAccrual
MetricsSubject Accrual Performance

 

P                   A

	Study No.:	Total No. Sites:
	Study Short Name:	Total No. Subjects:
	Registration No.:	Monthly Subject Accrual:
	Test Article:	 
	Study Type:	 
	Study Status: Planned	 

 

 

 

 

Study Milestones Timeline

 

 

 

    	18Exhibit 10.4

 

MASTER SERVICES AGREEMENT

 

THIS MASTER SERVICES AGREEMENT (“Agreement”)
is made as of this 7th day of April, 2014 (“Effective Date”) by and among ViruSure GmbH, an Austrian corporation, with
a business address at Tech Gate Science Part, Donau City Strasse 1, A-1220, Vienna, Austria (“VIRUSURE”) and Nuvilex,
Inc., a Nevada corporation, with a business address at 12510 Prosperity Drive, Suite 310, Silver Spring, Maryland 20904
U.S.A. (“COMPANY”).

 

BACKGROUND

 

VIRUSURE is a contract research organization
engaged in providing products and services including, without limitation, discovery and development services, preclinical, clinical
and commercial testing services, scientific and regulatory consulting and research models and related services. COMPANY desires
VIRUSURE to provide and VIRUSURE agrees to provide the services described in this Agreement (“Services”) pursuant to
the terms and conditions of this Agreement. The Services shall consist of individual studies or consultations (each, a “Study”)
defined in the Supporting Documents (as hereinafter defined). In consideration of the mutual promises and covenants set forth herein
and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties, intending
to be legally bound, agree as follows:

 

1.     
The Study. VIRUSURE shall render the Services as set forth in a Protocol and/or Statement of Work, Letter of Payment
Authorization, Letter of Agreement, Letter of Commitment, Work Order, Purchase Order or Consulting Services Letter (the Protocol
and/or Statement of Work, Letter of Payment Authorization, Letter of Agreement, Letter of Commitment, Work Order, Purchase Order
and Consulting Services Letter are collectively referred to in this Agreement as the “Supporting Documents”). A “Protocol”
and/or “Statement of Work” shall mean an attachment to this Agreement describing the nature, design and scope of the
Study and the schedule of work to be performed or consulting services to be provided during the course of an individual Study conducted
by VIRUSURE for COMPANY. A “Letter of Payment Authorization”, “Letter of Agreement”, “Work Order”
or “Purchase Order” shall mean an attachment to this Agreement that describes with respect to a particular Study the
price, fees and payment schedule for that Study and any modifications of the terms of this Agreement as applied to a particular
Study. A “Letter of Commitment” shall mean an attachment to this Agreement that describes a commitment of space and
resources by VIRUSURE. A Consulting Services Letter shall mean an attachment to this Agreement that describes VIRUSURE’s
consulting services and pricing for such services. In the event of a conflict between the terms contained in the Supporting Documents
and this Agreement, the terms of this Agreement shall control, unless specifically agreed upon to the contrary in the Supporting
Documents. The Supporting Documents when signed by VIRUSURE and COMPANY shall be incorporated into and made a part of this Agreement.

 

2.     
Conduct of Services. 

 

2.1.
 VIRUSURE will maintain industry standards of professional conduct in the performance of the Study and in the preparation
of all related reports. VIRUSURE and COMPANY will adhere to all material government laws, rules and regulations applicable to the
conduct of the Study (“Applicable Law”). If applicable, and as set forth in the Supporting Documents, VIRUSURE will
perform the Study in compliance with the current Good Laboratory Practices (“GLP”) or Good Manufacturing Practices
(“GMP”) of the appropriate governmental regulatory agencies.

 

2.2. VIRUSURE will conduct
the Study in accordance with the Supporting Documents, which may be amended from time to time upon the mutual agreement of
VIRUSURE and COMPANY. VIRUSURE agrees not to intentionally change or deviate in any material manner from the Supporting
Documents without COMPANY’s prior approval. Deviations from the Supporting Documents may be made in an emergency
without COMPANY’s approval, provided that VIRUSURE shall use commercially reasonable efforts to obtain COMPANY’s
verbal approval, which shall be subsequently confirmed by COMPANY in writing. The parties acknowledge that during the course
of performing the Study in accordance with the Supporting Documents, additional costs may be incurred by VIRUSURE as a result
of procedural changes which do not amount to or require a change in the Supporting Documents, but which are deemed necessary
by VIRUSURE to successfully perform said Study, and which could not be foreseen at the time of the preparation of the
Supporting Documents. If such procedural changes occur, VIRUSURE shall advise COMPANY prior to their implementation and
obtain COMPANY's prior written approval as to the necessity and additional cost thereof. Should such changes be urgent, and
VIRUSURE is unable to obtain COMPANY’s written approval in advance, VIRUSURE shall use commercially reasonable efforts
to obtain COMPANY’s verbal approval, which shall be subsequently confirmed by COMPANY in writing. Upon obtaining such
approval, COMPANY agrees that in order to maintain the integrity of the Study, VIRUSURE may proceed accordingly and be
entitled to recover such additional costs from COMPANY upon presentation of an explanation of such procedural changes,
urgency and the necessity thereof. VIRUSURE shall not subcontract all or a part of the Services to a third party
without obtaining prior written consent of COMPANY.

 

    	1

    	 

    

 

2.3. After
the Study has been completed, VIRUSURE may be requested by COMPANY to provide additional consultation services concerning the Study.
Upon such a request by COMPANY, VIRUSURE will provide the requested services and will be paid an amount mutually agreed to between
COMPANY and VIRUSURE. These consultation services will be subject to the provisions on Confidentiality and Ownership set forth
in Sections 8 and 13 of this Agreement, respectively.

 

3.     
Test Articles. If applicable, COMPANY will provide VIRUSURE with sufficient amounts of all compounds, materials, or
other substances meeting relevant specifications (“Test Articles”) with which to perform the Study, as well as such
complete and accurate data as is necessary to apprise VIRUSURE of the identity, strength, purity, stability and composition or
other appropriate characteristics of each batch, proper storage and safe handling requirements of Test Articles, including a Material
Safety Data Sheet (“MSDS”) or equivalent documentation (e.g. Genetically Modified Organism (“GMO”) assessment),
such as Sample Submission Form that is provided and requested by VIRUSURE. In addition, COMPANY
will provide VIRUSURE certification that the methods of synthesis, fabrication, or derivation of Test Articles had been documented
by COMPANY. COMPANY will arrange shipments of Test Articles. All costs associated with shipping Test Articles to VIRUSURE shall
be the responsibility of COMPANY, and VIRUSURE shall not be responsible for any loss, damage or destruction of the Test Articles
while in transit.

 

4.     
Personnel. VIRUSURE will arrange for qualified personnel to support VIRUSURE’s obligations under this Agreement.
To the best of VIRUSURE’s knowledge, VIRUSURE represents that none of its employees who are to participate in a Study have
been debarred and none of such employees are under consideration to be debarred by the U.S. Food and Drug Administration from working
in or providing services to any pharmaceutical or biotechnology company under the Generic Drug Enforcement Act of 1992, as amended.

 

5.     
Inspections. 

 

5.1. Upon
reasonable advance notice, VIRUSURE will permit COMPANY, during normal business hours and at mutually agreeable times, to
visit the VIRUSURE facilities where the Study is taking place to monitor VIRUSURE’s performance of the Study.

 

5.2. VIRUSURE
will notify COMPANY as soon as practical in the event of any regulatory inspection of VIRUSURE’s facilities that
directly impacts a Study. In the event of an inspection of COMPANY’s Study by a regulatory or administrative agency,
VIRUSURE will to the extent permissible under Applicable Law, consult with and allow COMPANY to review and comment on any
responses to such agency related to the inspection.

 

5.3. To the
extent that COMPANY engages a third party to perform any services related to a Study, COMPANY shall provide all information
requested by VIRUSURE regarding such services, including without limitation all information regarding regulatory and quality
assurance sufficient to enable VIRUSURE to comply with its own regulatory and/or quality assurance obligations.

 

    	2

    	 

    

 

6.     
Records and Reports.

 

6.1. VIRUSURE
will keep complete and accurate records of the status and progress of the Study as required by the Supporting Documents.

 

6.2.
Provided that COMPANY is not in default hereunder or under any of the Supporting Documents, VIRUSURE will furnish a report or
data containing information specified in the Supporting Documents. All reports will be prepared in the standard format of the
VIRUSURE unless otherwise specified in the Supporting Documents or as otherwise agreed to by the parties.

 

6.3.
All raw data, study documentation, protocols, interim and final reports, specimens generated as a result of a
preclinical, clinical and/or commercial Study (“Deliverables”) are COMPANY’s property. At COMPANY’s
cost and expense, if Applicable Law or COMPANY requires COMPANY’s property to be held by VIRUSURE, VIRUSURE shall store
COMPANY’s property as agreed upon in the Supporting Documents and in accordance with VIRUSURE’s standard
archiving terms and conditions set forth on Exhibit A attached to this Agreement and made a part hereof. Upon reasonable
advance notice, provided that COMPANY is not in default under this Agreement or under any of the Supporting Documents,
COMPANY shall have reasonable access to such material, and shall have the right to obtain photocopies of the raw data and
supporting documentation, at COMPANY’s expense. Upon request and at the expense of COMPANY, VIRUSURE will assist
COMPANY in transferring any of COMPANY’s property to a third party as instructed by COMPANY.

 

6.4.
In the event VIRUSURE provides electronic access to the Study data, records, reports and other documentation and COMPANY
elects to use such electronic access, the use of such electronic access shall be governed by VIRUSURE’s
standard electronic access terms and conditions which may be accessed via VIRUSURE’s website.

 

7.     
Compensation. 

 

7.1. COMPANY
will pay VIRUSURE as set forth in the Supporting Documents (“Study Price”). All invoices are due and payable thirty
(30) days from the date of Company’s receipt of the invoice, and COMPANY agrees to pay all invoices submitted. All amounts
not paid by COMPANY when due shall accrue interest from the applicable due date until paid, at the rate of one and one half percent
(1.5%) per month. VIRUSURE may elect to cease or suspend work on a Study or withhold required reports or other deliverables if
COMPANY does not make payments when due and payable.

 

7.2.
All applicable termination, delay, suspension or cancellation fees will be set forth in the Supporting Documents.

 

7.3. COMPANY and VIRUSURE
agree that neither COMPANY nor VIRUSURE should receive a benefit or a detriment from differences arising from variations
between foreign currency exchange rates for the currencies used for this project and those existing at the dates of the
actual invoices, as published in the Wall Street Journal. If such a difference is larger than +/- 5%, COMPANY and VIRUSURE
have the right to request a re-evaluation of the future billing rates based on the work performed by VIRUSURE after such a
difference is observed.

 

7.4. All Value Added Taxes,
sales taxes and any other taxes required by Applicable Law shall be paid by COMPANY.

 

8.     
Confidentiality. The parties may exchange proprietary and confidential information during the term of this Agreement, including,
without limitation, the existence and terms of this Agreement. The parties will identify, in writing, such information as confidential
and/or proprietary. If a party intends to disclose confidential information to the other party orally, the disclosing party shall:
(i) alert the other party of the confidential nature of the disclosure prior to the disclosure; and (ii) provide written notice
to the other party of the confidential nature and contents of such disclosure within ten (10) days of the original disclosure.
Each party will use its commercially reasonable efforts to maintain such information in confidence and will employ reasonable and
appropriate procedures to prevent its unauthorized publication or disclosure. Except as expressly authorized in writing, neither
party shall use the other party’s proprietary or confidential information for any purpose other than in performance of this
Agreement. The obligations of confidentiality set forth in Section 8 of this Agreement will survive the termination or expiration
of this Agreement for a period of five (5) years. The confidentiality provisions of Section 8 of this Agreement shall not apply
to any part of such information, which:

 

		a)	is known to the receiving party at the time it was obtained from the disclosing party;

 

    	3

    	 

    

 

 

		b)	is acquired by the receiving party from a third party, and such third party did not obtain such
information directly or indirectly from the disclosing party under an obligation not to disclose;

 

		c)	is or becomes published or otherwise in the public domain other than by violation of this Agreement
by the receiving party;

 

		d)	is independently developed by the receiving party without reference to or reliance upon the information
provided by the disclosing party; and

 

		e)	is required to be disclosed by the receiving party to comply with applicable laws or governmental
regulations; provided that the receiving party provides prompt written notice of such disclosure to the disclosing party and cooperates
with the disclosing party’s reasonable and lawful actions to avoid and/or minimize the extent of such disclosure.

 

9.     
Use of Names.

 

Neither party will use the other party’s
name or the name of any employee of the other party in any advertising, packaging, promotional material, or any other publicity
relating to this Agreement, without the prior written approval of the other party.

 

10.   Warranties.

 

10.1. COMPANY
warrants that it owns all rights, title and interest in or otherwise has the right to use the Test Articles and
the intellectual property related thereto, and that, to the best of COMPANY’s knowledge, VIRUSURE’s use of any
and all such Test Articles in connection with any Study will not infringe the intellectual property rights of any third
party.

 

10.2. VIRUSURE
warrants that the Services shall conform to the specifications set forth in the
Supporting Documents, Applicable Law and the current material applicable standards, regulations and procedures of the
appropriate regulatory agencies. VIRUSURE neither warrants nor represents that the results of the Study will be acceptable to
any regulatory or governmental agency to which they are presented nor that the results of the Study will enable COMPANY to
further develop, market or otherwise exploit the Test Articles or any other product or service.

 

10.3. THE
WARRANTY BY COMPANY SET FORTH IN SECTION 10.2 ABOVE IS IN LIEU OF ANY AND ALL OTHER REPRESENTATIONS OR WARRANTIES,
EXPRESS, IMPLIED OR STATUTORY INCLUDING, WITHOUT LIMITATION, ANY IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A
PARTICULAR PURPOSE OR FOR NON-INFRINGEMENT OF A PATENT, TRADEMARK OR OTHER INTELLECTUAL PROPERTY RIGHT. 

 

11.     Limitation
of Liability. 

 

11.1. In as
far as no other terms or conditions have been agreed, the VIRUSURE’s liability in the event of any claim is limited to
the performance of the Services. VIRUSURE is exempt from honouring compensation, in particular for any damages beyond the
performance of the Services, unless gross negligence or wilful misconduct can be proven. This clause shall continue to be
effective without limit of time after the expiration or termination of the Services.

 

11.2. VIRUSURE
will not be liable for penalties or liquidated damages or for special, indirect, consequential, punitive, exemplary or
incidental damages of any type or kind (including, without limitation, lost profits) regardless of whether any such losses
or damages are characterized as arising from breach of contract, breach of warranty, tort, strict liability or otherwise,
even if VIRUSURE is advised of the possibility of such losses or damages, or if such losses or damages are foreseeable.

 

 

    	4

    	 

    

 

11.3. VIRUSURE’s
liability under this Agreement, regardless of the form of action, shall be limited to actual damages and shall not exceed the
total amount paid for the Protocol or Statement of Work under which such liability arises, except to the extent caused by
gross negligence or wilful misconduct of the VIRUSURE. In no event shall either VIRUSURE be liable for any damages
arising from or in connection with any decision by COMPANY or any third party, made independently of the Services or
VIRUSURE’s confidential information provided under this Agreement, to further research, develop or market Test Articles
or any derivative or product or service related thereto or the use of Test Articles or any product or derivative or service
related thereto.

 

11.4. Subject to the
limitations set forth in this Section 11, in the event that VIRUSURE commits a breach of the warranty set forth in Section
10.2 above, VIRUSURE’s sole liability, and COMPANY’s sole remedy, shall be for VIRUSURE to perform, at
VIRUSURE’s cost and expense, the affected work or portion of the research affected by the breach to the relevant
specification.

 

12.     Indemnities.

 

12.1. Subject
to the limitations of liability contained in Section 11 of this Agreement above, VIRUSURE will defend, indemnify, save and
hold harmless COMPANY and its parent, subsidiaries and affiliates, and their respective directors, officers, employees
and agents, from and against any claims, demands, lawsuits, actions, causes of action, losses, damages, fines and
liabilities, including, without limitation, reasonable attorneys’ fees and any costs and expenses associated with each
party’s compliance with a subpoena or other similar legal request related to a Study (“Claims”) arising out
of or in connection with or attributable to VIRUSURE’s breach of this Agreement, gross negligence or wilful misconduct
in performance of the Study and will pay any costs and damages which may be assessed against them, provided that VIRUSURE is
given written notice of the Claims within ten (10) days of the date of notice to COMPANY and is given information, reasonable
assistance and sole authority to defend the Claims, provided that no settlement of such Claims may be effected by VIRUSURE
without COMPANY’s written consent (which consent will not be unreasonably withheld).

 

12.2. COMPANY
will defend, indemnify, save and hold harmless VIRUSURE and its parent, subsidiaries and affiliates, and their respective
directors, officers, employees and agents, from and against any Claims arising out of or in connection with or attributable
to: (i) the research, development, manufacture, distribution, use, sales or other disposition by COMPANY, or any distributor,
collaborator, customer, sub-licensee, contractor, subcontractor, representative or agent of COMPANY, of the Test Articles
and/or any other substances upon which the services of VIRUSURE were performed, except to the extent such Claims arise from
VIRUSURE’s breach of this Agreement, or gross negligence or wilful misconduct of VIRUSURE; or (ii) any infringement of
any third party’s patent rights or unauthorized use or misappropriation of its know-how related to the Study, except to
the extent such Claims arise from or in connection with the intellectual property, confidential information or
other techniques of VIRUSURE employed in the performance of the Services; or (iii) COMPANY’s breach of this Agreement,
gross negligence or wilful misconduct in connection with this Agreement and will pay any costs and damages which may be
assessed against them, provided that COMPANY is given written notice of the Claims within ten (10) days of the date of notice
to VIRUSURE and is given information, reasonable assistance and sole authority to defend the Claims, provided that no
settlement of such Claims may be effected by the VIRUSURE without COMPANY’s written consent (which consent will not be
unreasonably withheld). 

 

13.     Ownership.
Any inventions and/or techniques for carrying out the Services which relate to the conduct of VIRUSURE’s business are and
shall remain VIRUSURE’s exclusive property, including, but not limited to; present and future documentation, scientific and
technical data, test procedures and other information that is owned or licensed by VIRUSURE and that is not developed hereunder.
Subject to the terms and conditions hereof, VIRUSURE shall have the right to use concurrent control data as part of its general
historical database. Any data, discoveries or inventions developed or generated pursuant to this Agreement which directly relate
to any information or materials (including Test Articles) provided by COMPANY under this Agreement or those relating to Deliverables,
including, without limitation, new data, uses, processes or compositions directly relating to the information or materials (including
Test Articles) provided under this Agreement or those relating to Deliverables shall be the exclusive property of COMPANY. VIRUSURE
agrees to assist COMPANY in securing for COMPANY any patents, copyrights or other proprietary rights in such data, discoveries
or inventions and to perform all acts that may be reasonably required to vest in COMPANY all right, title and interest in such
data, discoveries or inventions, and VIRUSURE shall be reasonably compensated for such assistance. All costs and expenses associated
with establishing COMPANY’s rights therein shall be COMPANY’s responsibility.

 

    	5

    	 

    

 

14.    
Force Majeure. Except with respect to the payment of monies due under this Agreement, neither party shall be considered in
default of the performance of any obligation hereunder to the extent that the performance of such obligation is prevented or delayed
by fire, flood, earthquake, hurricane, explosion, disease, contamination, strike,
acts of terrorism, war, insurrection, embargo, government requirement, civil or military authority, act of God, or any other event,
occurrence or condition which is not caused, in whole or in part, by that party, and which is beyond the reasonable control of
that party.

 

15.     Term
and Termination. 

 

15.1. This
Agreement will commence on the Effective Date and will continue for five (5) years
from the Effective Date or until terminated by the parties as set forth below.

 

15.2. COMPANY shall have the
right to terminate an on-going Study at any time without cause upon thirty (30) days prior written notice to VIRUSURE. In the
event a Study is terminated without cause, VIRUSURE shall be paid for all Services rendered through the effective date of
termination, together with any additional expenses incurred in connection with the shutdown of the Study, including, without
limitation, any irrevocably committed costs incurred by VIRUSURE.

 

15.3. Either party may
terminate this Agreement upon thirty (30) day’s notice to the other party, provided that VIRUSURE completes all Studies
in progress and COMPANY makes all payments due to VIRUSURE through the effective date of termination date as set forth in
Section 16.2.

 

15.4. Upon termination,
neither party will have any further obligations under this Agreement, except that: (i) the liabilities accrued through the
effective date of termination; and (ii) the obligations which by their terms survive termination, including the applicable
confidentiality, record keeping, regulatory compliance, intellectual property and indemnification provisions of this
Agreement, shall survive termination.

 

16. Employee Solicitation.
COMPANY agrees that, during the term of a Study and for a period of one hundred eighty (180) days thereafter, COMPANY will
not solicit for hire or hire as an employee, or engage as an independent contractor, any person who has been involved in
rendering services on the Study, without the prior written consent of VIRUSURE. In the event of such solicitation, hiring or
engagement, in addition to any other remedy VIRUSURE may have, COMPANY shall pay to VIRUSURE an amount equal to such
employee’s annual salary.

 

17.
Dispute Resolution. The parties shall attempt, in good faith, to resolve through negotiations any controversy, claim, or
dispute arising out of this Agreement. In the event that negotiations are not successful, the
controversy, claim or dispute shall be submitted to third party mediation upon terms reasonably acceptable to the parties. If
such claim, controversy or dispute is not resolved through mediation, upon written demand of either party, the claim,
controversy or dispute shall be submitted to arbitration. Such arbitration shall take place and proceed in accordance with
the laws of Austria and rules of Conciliation and Arbitration of the International Chamber of Commerce. A record and
transcript of the proceedings shall be maintained. Any award shall be made in writing and in reasonable
detail, setting forth the findings of fact and conclusion of law supporting the award. The determination of a majority of the
panel of arbitrators shall be the decision of the arbitrators, which shall be binding regardless of whether one of the
parties fails or refuses to participate in the arbitration. The decision shall be enforceable by a court of law, provided
that the decision is supported by substantial fact and is without material error of law. All costs of such arbitration,
except expert fees and attorneys’ fees, shall be shared equally by the parties. 

 

18. Miscellaneous. 

 

18.1. Notices. All notices
from one party to the other will be in writing and will be delivered by addressing the same to the addresses first set forth
above, or at such other address as either party may specify in writing to the other. Notices shall be sent by overnight
courier, certified mail, return receipt requested, or by other means of delivery requiring a written acknowledged receipt.
All notices shall be effective upon receipt.

 

    	6

    	 

    

 

18.2. Independent Contractor.
The business relationship of VIRUSURE to COMPANY is that of an independent contractor and not of a partner, joint venture, employer,
employee or any other kind of relationship. VIRUSURE will be solely responsible for expenses and liabilities associated with the
employment of its employees.

 

18.3.
Assignment. This Agreement, and the rights and obligations under this Agreement, may not be assigned or transferred by
either party without the prior written consent of the other party, except that either party may assign this Agreement to an
affiliated company or in connection with the merger, consolidation or sale of substantially all assets related to the
Study.

 

18.4. Entire
Agreement. This Agreement, together with the Supporting Documents, sets forth the entire agreement and understanding
between the parties, superseding any and all previous statements, negotiations, documents agreements and understandings,
whether oral or written, as to the subject matter of the Agreement. No modification or waiver of the provisions of this
Agreement shall be valid or binding on either party unless in writing and signed by both parties. No waiver of any term,
right or condition under this Agreement on any one occasion shall be construed or deemed to be a waiver or continuing waiver
of any such term, right or condition on any subsequent occasion or a waiver of any other term, right or condition
hereunder.

 

18.5.
Severability. In the event that any one or more of the provisions contained in this Agreement is for any reason, held to
be invalid, illegal or unenforceable in any respect, that invalidity, illegality or unenforceability will not affect any
other provisions of this Agreement, and all other provisions will remain in full force and effect. If any provision of this
Agreement is held to be excessively broad, it will be reformed and construed by limiting and reducing it so as to be
enforceable to the maximum extent permitted by law.

 

18.6. Applicable Law.
This Agreement will in all events and for all purposes be governed by, and construed in accordance with, the laws of Austria
without regard to any choice of law principle that would dictate the application of the law of another jurisdiction.

 

18.7. Counterparts.
This Agreement may be executed in counterparts, which taken together shall constitute a single legal document.

 

18.8. Language of Agreement.
The parties acknowledge that it is their express wish that this Agreement and all notices and other documents to be given or executed
pursuant hereto be in English.

 

 

    	7

    	 

    

 

 

IN WITNESS WHEREOF,
duly authorized representatives of the parties have executed and delivered this Agreement as of the Effective Date.

 

	 ViruSure	 	Nuvilex, Inc.
	
        By: /s/ Andy Bailey                            
	 	
        By: /s/ Kenneth L. Waggoner                     

	Print Name: Andy Bailey  	 	Print Name: Kenneth L. Waggoner  
	Title: CEO/Operations Director	 	Title: Chief Executive Officer and President
	Date: April 7, 2014   	 	Date: April 7, 2014

 

 

 

 

    	8

    	 

    

 

 

 

Exhibit A

 

Archive Terms and Conditions

 

		1.	All raw data, study documentation, protocols, interim and final reports, specimens generated as
a result of a preclinical Study or case histories generated as a result of a clinical or commercial Study that COMPANY requests
be held in VIRUSURE’s archive facility or that Applicable Law requires be held in VIRUSURE’s archive facility shall
hereinafter be referred to as “Materials.” VIRUSURE agrees to comply with industry standards in connection with the
storage of the Materials and adhere to all Applicable Law with respect to the storage of the Materials.

 

		2.	VIRUSURE shall store the Materials at its current storage rates, which may be increased on an annual
basis upon agreement between VIRUSURE and COMPANY. If the Materials require additional and/or special storage requirements, additional
charges for storage shall be assessed and invoiced to COMPANY. Invoices shall be due and payable thirty (30) days from the date
of the invoice and COMPANY agrees to pay all invoices submitted.
	 	 	 

		3.	VIRUSURE’s liability for archival services under this Agreement, regardless of the form of
action, shall not exceed the fee paid for one year’s storage of the Materials, except to the extent caused by the breach
of this Agreement, the gross negligence or wilful misconduct byVIRUSURE. In no event shall VIRUSURE be liable for penalties or
liquidated damages or for special, indirect, consequential punitive, exemplary or incidental damages of any type or kind (including,
without limitation, lost profits) in connection with the storage of the Materials. VIRUSURE shall have no liability for loss of
the Materials beyond its reasonable control, including losses caused by loss of refrigeration.
	 	 	 

		4.	The Materials shall be archived for the period set forth in the Supporting Documents (“Retention
Period”). Upon the expiration of the Retention Period, VIRUSURE shall contact COMPANY to determine disposition of the Materials
as follows: (i) extended storage of the Materials; (ii) return of the Materials to COMPANY at COMPANY’s expense to be archived
in accordance with Applicable Law or (iii) where offered by VIRUSURE , disposal of Materials at COMPANY’s expense. If COMPANY
requests VIRUSURE to continue to store the Materials and VIRUSURE agrees, the cost for storage of the Materials shall continue
to be invoiced to COMPANY at VIRUSURE’s then current rates. If COMPANY fails to give such instructions, VIRUSURE shall so
notify COMPANY, and if such instructions are still not forthcoming within thirty (30) days of said notification, then VIRUSURE
shall have the option of (i) continuing storage of the Materials, which will be deemed to have been authorized for an additional
period of not less than one (1) year, or (ii) VIRUSURE may return the Materials to COMPANY at COMPANY’s expense or (iii)
dispose of the Materials at COMPANY’s expense provided regulatory retention periods have expired. If COMPANY intends to go
out of business or to transfer ownership of the Materials, COMPANY will provide notice to VIRUSURE with instructions for disposition
of the Materials. If COMPANY fails to give such instructions, VIRUSURE shall dispose of the Materials at COMPANY’s expense
provided regulatory retention periods have expired. COMPANY agrees that VIRUSURE shall have access to the Materials at all times
in order to comply with Applicable Law. COMPANY shall be liable for storage charges until the Materials are returned to COMPANY.
At any time while the Materials are in transit to COMPANY, all risk of loss or exposure to the Materials shall be borne by VIRUSURE.

 

		5.	VIRUSURE will not release the Materials to any third party, without COMPANY's written permission
unless such disclosure is compelled by valid subpoena or Applicable Law. If such disclosure is requested, VIRUSURE shall use its
commercially reasonable efforts to provide COMPANY with written notice prior to such release. Prior to release or inspection of
any Materials by COMPANY or its agents, COMPANY shall provide all reasonable documentation requested by VIRUSURE.

 

 

    	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00233-of-00352.parquet"}]]